Status:
COMPLETED
Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Allergic Rhinitis
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
Investigate safety/tolerability after a single dose intranasal administration of AZD8848 comparator placebo to healthy male volunteers and seasonal allergic rhinitis male patients out of season
Eligibility Criteria
Inclusion
- History of birch and/or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years
- Body mass index (BMI) between 19 and 30 kg/ m2 and a weight between 50 and 100 kg
- No clinically relevant abnormal findings
Exclusion
- Acute illness which requires medical intervention
- Definite or suspected personal history of adverse drug reactions or drug hypersensitivity
- Clinical relevant disease or disorder (past or present)
- A history of asthma
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00688779
Start Date
January 1 2008
End Date
April 1 2009
Last Update
August 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Lund, Sweden